Literature DB >> 29385596

Optimized Methods to Explore the Mechanistic and Biomarker Potential of Hepatocyte-Derived Exosomes in Drug-Induced Liver Injury.

Sarah E Thacker1, Manisha Nautiyal1, Monicah A Otieno2, Paul B Watkins1, Merrie Mosedale1.   

Abstract

Recent evidence supports that alterations in hepatocyte-derived exosomes (HDE) may play a role in the pathogenesis of drug-induced liver injury (DILI). HDE-based biomarkers also hold promise to improve the sensitivity of existing in vitro assays for predicting DILI liability. Primary human hepatocytes (PHH) provide a physiologically relevant in vitro model to explore the mechanistic and biomarker potential of HDE in DILI. However, optimal methods to study exosomes in this culture system have not been defined. Here we use HepG2 and HepaRG cells along with PHH to optimize methods for in vitro HDE research. We compared the quantity and purity of HDE enriched from HepG2 cell culture medium by 3 widely used methods: ultracentrifugation (UC), OptiPrep density gradient ultracentrifugation (ODG), and ExoQuick (EQ)-a commercially available exosome precipitation reagent. Although EQ resulted in the highest number of particles, UC resulted in more exosomes as indicated by the relative abundance of exosomal CD63 to cellular prohibitin-1 as well as the comparative absence of contaminating extravesicular material. To determine culture conditions that best supported exosome release, we also assessed the effect of Matrigel matrix overlay at concentrations ranging from 0 to 0.25 mg/ml in HepaRG cells and compared exosome release from fresh and cryopreserved PHH from same donor. Sandwich culture did not impair exosome release, and freshly prepared PHH yielded a higher number of HDE overall. Taken together, our data support the use of UC-based enrichment from fresh preparations of sandwich-cultured PHH for future studies of HDE in DILI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29385596     DOI: 10.1093/toxsci/kfy015

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

Review 1.  A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.

Authors:  Brandy Garzel; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

2.  Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury.

Authors:  Natalie S Holman; Rachel J Church; Manisha Nautiyal; Kelly A Rose; Sarah E Thacker; Monicah A Otieno; Kristina K Wolf; Edward LeCluyse; Paul B Watkins; Merrie Mosedale
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

3.  Propagation of Pericentral Necrosis During Acetaminophen-Induced Liver Injury: Evidence for Early Interhepatocyte Communication and Information Exchange.

Authors:  Ryan C Kennedy; Andrew K Smith; Glen E P Ropella; Mitchell R McGill; Hartmut Jaeschke; C Anthony Hunt
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

Review 4.  Advances in the application of mesenchymal stem cells, exosomes, biomimetic materials, and 3D printing in osteoporosis treatment.

Authors:  Xiao-Yu He; Hai-Ming Yu; Shu Lin; Yi-Zhong Li
Journal:  Cell Mol Biol Lett       Date:  2021-11-14       Impact factor: 5.787

5.  Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression.

Authors:  Raju Khatri; Natasha Kulick; Rebecca J B Rementer; John K Fallon; Craig Sykes; Amanda P Schauer; Melina M Malinen; Merrie Mosedale; Paul B Watkins; Angela D M Kashuba; Kim A Boggess; Philip C Smith; Kim L R Brouwer; Craig R Lee
Journal:  J Pharm Sci       Date:  2020-09-12       Impact factor: 3.534

Review 6.  Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives.

Authors:  Siyu Fu; Dongbo Wu; Wei Jiang; Juan Li; Jiang Long; Chengyao Jia; Taoyou Zhou
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.